The 12 most common content strategy mistakes and how to fix them for healthcare and life sciences in the Middle East
Every mistake we see teams make with content strategy — starting with the ones that cost the most and are the cheapest to fix. Written for commercial leaders at healthtech, medtech, and life-sciences companies in the Middle East.
This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the Middle East. In this market, Middle Eastern buyers reward in-person credibility, sovereign fit, and patient sequencing, so the way you install content strategy has to be shaped to that reality from day one.
Every content strategy failure we have investigated maps to one of the mistakes below. They repeat because they are structurally easy to make.
Mistake one, the foundational one: confusing volume with authority. Fix by naming an owner and writing kill criteria before you spend a dollar.
Mistake two: mistaking volume for progress. Fix by making pieces cited by prospects during sales calls the only weekly headline number.
Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the Middle East it is compounded by the fact that senior-relationship access, not product is what actually gates growth. Content strategy is only useful here when it is pointed at both constraints at once.
Mistake three: buying tools before defining the workflow. Fix by drawing the workflow on paper first and buying only what the paper shows.
Mistake four: shipping without a quality gate. Fix by requiring a human eyeball on every artefact for the first four weeks.
Mistake five: ignoring the trigger. Content strategy works when the best assets close deals in the deck, not just on Google; without a real trigger the model is guesswork.
Mistake six through twelve: cascade from the first five. Fix the top five and most of the others resolve themselves inside a month.
Concretely for healthcare and life sciences in the Middle East: the healthcare teams that install this get past procurement instead of dying in it, and one sovereign or family-office win in the Middle East justifies a full year of program spend. That is the reason it is worth installing content strategy deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
Content · healthcare · Middle East — answered
- Does content strategy work for healthcare and life sciences in the Middle East?
- Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in the Middle East, Middle Eastern buyers reward in-person credibility, sovereign fit, and patient sequencing. The healthcare teams that install this get past procurement instead of dying in it.
- What is the most expensive content strategy mistake?
- Confusing volume with authority — because it silently degrades every downstream metric.
- Which mistake is cheapest to fix?
- Missing kill criteria. Write them in an hour and save a quarter of budget.
- Can I skip the quality gate?
- Not in the first four weeks. After the model is proven, you can automate parts of it.
- How do I know a mistake is compounding?
- Pieces cited by prospects during sales calls stalls or drops for two consecutive weeks. That is your alarm.
- What is the Middle East-specific pitfall when running content strategy for healthcare?
- Importing a playbook that was built for another market. In the Middle East, Middle Eastern buyers reward in-person credibility, sovereign fit, and patient sequencing — the install has to reflect that.
Growth Broker editorial
Filed under content · healthcare · middle east